Chimeric antigen receptors (CAR) are recombinant receptors that provide both antigen-
binding and T-cell–activating functions. A multitude of CARs has been reported over the past …

Long-term engraftment of allogeneic cells necessitates eluding immune-mediated rejection,
which is currently achieved by matching for human leukocyte antigen (HLA) expression …

Adoptive transfer of T cells expressing a CD19-specific chimeric antigen receptor (CAR) is
being evaluated in multiple clinical trials. Our current approach to adoptive immunotherapy …

Cancer therapy with T cells expressing chimeric antigen receptors (CARs) has produced
remarkable clinical responses in recent trials, but also severe side effects. Whereas most …

Clinical trials targeting CD19 on B-cell malignancies are underway with encouraging anti-
tumor responses. Most infuse T cells genetically modified to express a chimeric antigen …

The broaden application of adoptive T-cell transfer has been constrained by the technical
abilities to isolate and expand antigen-specific T cells potent to selectively kill tumor cells …

Introduction: The development of chimeric antigen receptor (CAR)-modified immune cells
has become a highly active field of research since the introduction of this approach in 1989 …

Purpose We have incorporated a positron emission tomography (PET) functionality in T cells
expressing a CD19-specific chimeric antigen receptor (CAR) to non-invasively monitor the …

Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment
of chronic lymphocytic leukemia (CLL). To overcome issues of immune tolerance which …

Adoptive cell therapy truly began with the introduction of hematopoietic stem cell
transplantation. The ability to manipulate genes through cloning and expression …